IVERIC bio Management
Management criteria checks 3/4
IVERIC bio's CEO is Glenn Sblendorio, appointed in Jul 2017, has a tenure of 6.17 years. total yearly compensation is $9.82M, comprised of 7.1% salary and 92.9% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $9.56M. The average tenure of the management team and the board of directors is 5.5 years and 4.6 years respectively.
Key information
Glenn Sblendorio
Chief executive officer
US$9.8m
Total compensation
| CEO salary percentage | 7.1% |
| CEO tenure | 6yrs |
| CEO ownership | 0.2% |
| Management average tenure | 5.5yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate
Sep 06IVERIC bio Q2 2022 Earnings Preview
Jul 25Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura
Jul 05IVERIC bio: A First Take
Jun 23We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely
May 20
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation
Feb 01IVERIC bio (NASDAQ:ISEE) Is In A Good Position To Deliver On Growth Plans
Nov 03Estimating The Intrinsic Value Of IVERIC bio, Inc. (NASDAQ:ISEE)
Sep 28Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field
Sep 16Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation
Jul 02IVERIC bio discusses GATHER2 enrollment and retention updates and new GATHER1 post-hoc analyses
Jun 18IVERIC bio EPS misses by $0.04
May 05We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely
Mar 12We Think IVERIC bio (NASDAQ:ISEE) Can Afford To Drive Business Growth
Nov 27IVERIC bio EPS misses by $0.05
Nov 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$223m |
| Dec 31 2022 | US$10m | US$700k | -US$185m |
| Sep 30 2022 | n/a | n/a | -US$159m |
| Jun 30 2022 | n/a | n/a | -US$141m |
| Mar 31 2022 | n/a | n/a | -US$122m |
| Dec 31 2021 | US$6m | US$665k | -US$115m |
| Sep 30 2021 | n/a | n/a | -US$107m |
| Jun 30 2021 | n/a | n/a | -US$108m |
| Mar 31 2021 | n/a | n/a | -US$96m |
| Dec 31 2020 | US$4m | US$640k | -US$85m |
| Sep 30 2020 | n/a | n/a | -US$77m |
| Jun 30 2020 | n/a | n/a | -US$66m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$2m | US$599k | -US$59m |
| Sep 30 2019 | n/a | n/a | US$63m |
| Jun 30 2019 | n/a | n/a | US$62m |
| Mar 31 2019 | n/a | n/a | US$64m |
| Dec 31 2018 | US$1m | US$625k | US$63m |
| Sep 30 2018 | n/a | n/a | -US$51m |
| Jun 30 2018 | n/a | n/a | US$153m |
| Mar 31 2018 | n/a | n/a | US$144m |
| Dec 31 2017 | US$3m | US$560k | US$114m |
| Sep 30 2017 | n/a | n/a | US$57m |
| Jun 30 2017 | n/a | n/a | -US$192m |
| Mar 31 2017 | n/a | n/a | -US$200m |
| Dec 31 2016 | US$9m | US$373k | -US$193m |
Compensation vs Market: Glenn's total compensation ($USD9.82M) is about average for companies of similar size in the US market ($USD7.88M).
Compensation vs Earnings: Glenn's compensation has increased whilst the company is unprofitable.
CEO
Glenn Sblendorio (67 yo)
6yrs
Tenure
US$9,816,150
Compensation
Mr. Glenn P. Sblendorio, M.B.A., served as the President of IVERIC bio, Inc. (formerly, Ophthotech Corporation) since February 1, 2017 until May 01, 2021 and has been its Chief Executive Officer since July...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6yrs | US$9.82m | 0.17% $ 9.6m | |
| President & Director | 2.2yrs | US$4.63m | 0.15% $ 8.1m | |
| Senior VP | 6.3yrs | US$2.68m | 0.032% $ 1.8m | |
| Senior VP & COO | 6.5yrs | US$2.66m | 0.029% $ 1.6m | |
| Senior VP & Chief Commercial Officer | 1.9yrs | US$2.67m | 0.024% $ 1.3m | |
| Co-Founder and Consultant | 16.5yrs | no data | no data | |
| Chief Technical Officer | 2.5yrs | no data | no data | |
| Senior VP of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior VP | 5.4yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | 5.5yrs | no data | no data | |
| Senior VP & Chief Clinical Operations Officer | 7.5yrs | US$411.67k | no data | |
| Chief Strategist of Gene Therapy | 3.7yrs | no data | no data |
5.5yrs
Average Tenure
58yo
Average Age
Experienced Management: ISEE's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.2yrs | US$9.82m | 0.17% $ 9.6m | |
| President & Director | less than a year | US$4.63m | 0.15% $ 8.1m | |
| Independent Director | 15.9yrs | US$354.59k | 0.016% $ 882.5k | |
| Independent Chairman of the Board | 4.6yrs | US$398.34k | 0.016% $ 882.5k | |
| Independent Director | 3yrs | US$354.59k | 0.023% $ 1.3m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.5yrs | US$365.84k | 0.034% $ 1.9m | |
| Independent Director | 5.5yrs | US$385.84k | 0.016% $ 882.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.6yrs
Average Tenure
64yo
Average Age
Experienced Board: ISEE's board of directors are considered experienced (4.6 years average tenure).